Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908985 | Leukemia Research | 2014 | 4 Pages |
Abstract
For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3Â +Â 7 induction chemotherapy (24 patients). Response rates (PÂ =Â 0.014) and median overall survival (PÂ =Â 0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3Â +Â 7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (PÂ =Â 0.025), respectively. CLAG-M has encouraging activity in this patient group.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Michael V. Jaglal, Vu H. Duong, Celeste M. Bello, Najla H. Al Ali, Eric Padron, Hugo F. Fernandez, Alan F. List, Jeffrey E. Lancet, Rami S. Komrokji,